VIVUS LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-08
Last Posted Date
2009-12-01
Lead Sponsor
VIVUS LLC
Target Recruit Count
32
Registration Number
NCT00768404
Locations
🇺🇸

Advanced Clinical Research Institute, Anaheim, California, United States

🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

and more 1 locations

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-08
Last Posted Date
2009-12-01
Lead Sponsor
VIVUS LLC
Target Recruit Count
18
Registration Number
NCT00768209
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-09-03
Last Posted Date
2012-10-05
Lead Sponsor
VIVUS LLC
Target Recruit Count
45
Registration Number
NCT00745251
Locations
🇺🇸

Kentucky Research Group, Louisville, Kentucky, United States

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-08-19
Last Posted Date
2012-09-10
Lead Sponsor
VIVUS LLC
Target Recruit Count
101
Registration Number
NCT00737633
Locations
🇺🇸

Research Site, Richmond, Virginia, United States

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-01-24
Last Posted Date
2012-09-10
Lead Sponsor
VIVUS LLC
Target Recruit Count
130
Registration Number
NCT00600067
Locations
🇺🇸

Research Site, Richmond, Virginia, United States

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-11-26
Last Posted Date
2015-03-30
Lead Sponsor
VIVUS LLC
Target Recruit Count
756
Registration Number
NCT00563368
Locations
🇺🇸

Research Site, Philadelphia, Pennsylvania, United States

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

First Posted Date
2007-11-06
Last Posted Date
2012-09-10
Lead Sponsor
VIVUS LLC
Target Recruit Count
1267
Registration Number
NCT00554216
Locations
🇺🇸

Research, Ridgefield, Connecticut, United States

🇺🇸

Research Site, Austin, Texas, United States

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-11-06
Last Posted Date
2012-09-10
Lead Sponsor
VIVUS LLC
Target Recruit Count
2487
Registration Number
NCT00553787
Locations
🇺🇸

Research Site, Austin, Texas, United States

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-08-20
Last Posted Date
2011-06-08
Lead Sponsor
VIVUS LLC
Target Recruit Count
64
Registration Number
NCT00518466
Locations
🇺🇸

VIVUS, Inc., Mountain View, California, United States

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-06-14
Last Posted Date
2012-09-10
Lead Sponsor
VIVUS LLC
Target Recruit Count
210
Registration Number
NCT00486291
Locations
🇺🇸

Research Site, Richmond, Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath